Stock Taper
PROCEPT BioRobotics, founded in 2007 and based in California, develops and sells the AquaBeam Robotic System for minimally invasive urologic surgeries, primarily treating BPH, with 130 systems installed worldwide as of 2021.

The HYDROS Robotic System by PROCEPT BioRobotics, FDA-cleared in 2024, is an AI-powered surgical robot that enhances Aquablation therapy for BPH with advanced imaging, treatment planning, and streamlined workflow.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
TWST | $162.35 | COMPARE |
EWTX | $44.81 | COMPARE |
GRDN | $43.71 | COMPARE |
CLOV | $4.48 | COMPARE |
INSP | $75.52 | COMPARE |
MESO | $15.41 | COMPARE |
AORT | $23.36 | COMPARE |
QDEL | $10.82 | COMPARE |